Nexalin Technology (NXL) announced continued advancement toward its planned pivotal clinical trial evaluating HALO Clarity for the treatment of moderate to severe insomnia, designed to support Nexalin’s planned de novo submission to the U.S. Food and Drug Administration. The study is being conducted in collaboration with Lindus Health, a full-service clinical research organization engaged to oversee trial execution, regulatory preparation, and patient recruitment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin ‘commended’ recent Congressional initiative on neurostim research
- Nexalin Technology launches AI-designed virtual clinic platform NeuroCare
- Nexalin Technology highlights research validating neurostimulation technology
- Nexalin Faces Nasdaq Noncompliance Over Minimum Bid Price
- Nexalin Technology announces publication of peer-reviewed study on DIFS